A narrative review evaluating how to diagnose and manage candiduria across clinical scenarios — from asymptomatic colonization to invasive candidiasis — using a clinical vignette of a patient with a double-J ureteral stent and acute febrile illness, grounded in 2016 IDSA and 2025 ECMM guidelines.
No randomized controlled trials exist for symptomatic candiduria management; the review synthesizes observational data and expert guidance into practical clinical algorithms covering risk stratification, antifungal selection (based on renal diffusion and urinary excretion profiles), and management of rare complications like fungus balls.
Evidence base relies entirely on observational studies and expert opinion, with no RCTs addressing symptomatic candiduria treatment; findings are framed around a single clinical vignette, which may limit generalizability across diverse patient populations.
Distinguish colonization from true infection before initiating antifungals — most candiduria in hospitalized patients does not require treatment. When treatment is warranted, choose antifungals based on their urinary excretion profile (e.g., fluconazole excretes well renally) and apply antifungal stewardship principles, especially in ICU and urological settings.